Effects of 3-week oral treatment with the antioxidant thioctic acid (α- lipoic acid) in symptomatic diabetic polyneuropathy

Diabetic Medicine

Volumn 16, Issue 12, 1999, Pages 1040-1043

  Ruhnau, K J ^b   Meissner, H P ^b   Finn, J R ^c   Reljanovic, M ^h   Lobisch, M ^e   Schutte K ^e   Nehrdich, D ^f   Tritschler, H J ^g   Mehnert, H ^d   Ziegler, Dan ^a  

^a Deutsches Diabet Forsch Inst   (Germany)

^b Diabetologische Schwerpunktpraxen   (Germany)

^c Diabetes Care Akademie   (Germany)

^d Klinikum Schwabing   (Germany)

^e Medizinische Forschung   (Germany)

^f Biometrie   (Germany)

^g Zentrales Produktmanagement ASTA   (Germany)

^h NONE

Author keywords

Antioxidants; Diabetic polyneuropathy; Neuropathy Disability Score; Thioctic acid; Total Symptom Score

Indexed keywords

ANTIOXIDANT; THIOCTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MALE; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

AGED; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; THIOCTIC ACID;

EID: 0004570568     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00190.x     Document Type: Article

References (9)

1. 1 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. 2 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared to conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. 3 Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994; 10: 189-224.
4. 4 Ziegier D. Therapie der peripheren diabetischen Neuropathie. Diabetes Stoffwechsel 1998; 7: 1-11.
5. 5 Ziegler D, Hanefeld M, Ruhnau KJ, Meiβner HP, Lobisch M, Schütte L, Gries FA et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetolagia 1995; 38: 1425-1433.
6. 6 Gleiter CH, Schug BS, Hermann R, Elze M, Blume HH, Gundert-Remy U. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol 1996; 50: 513-514.
7. 7 Young MJ, Boulton AJM, Macleod AF, Williams DDR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
8. 8 Hoppe F. Hamburger Schmerz Adjektiv Liste (HSAL). Manual. Weinheim: Beltz-Verlag, 1991.
9. 9 Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997; 46: S38-S42.